Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 253

1.

Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years.

Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, Greenhalgh RM; EVAR-1, DREAM, OVER and ACE Trialists..

Br J Surg. 2017 Feb;104(3):166-178. doi: 10.1002/bjs.10430. Review.

2.

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.

Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA, Budelsky AL.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55. Review.

PMID:
27856660
3.

Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines.

Dietrich D, Martin P, Flacher V, Sun Y, Jarrossay D, Brembilla N, Mueller C, Arnett HA, Palmer G, Towne J, Gabay C.

Cytokine. 2016 Aug;84:88-98. doi: 10.1016/j.cyto.2016.05.012.

PMID:
27259168
4.

Sushi barcoding in the UK: another kettle of fish.

Vandamme SG, Griffiths AM, Taylor SA, Di Muri C, Hankard EA, Towne JA, Watson M, Mariani S.

PeerJ. 2016 Mar 31;4:e1891. doi: 10.7717/peerj.1891.

5.

Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage.

Medina-Contreras O, Harusato A, Nishio H, Flannigan KL, Ngo V, Leoni G, Neumann PA, Geem D, Lili LN, Ramadas RA, Chassaing B, Gewirtz AT, Kohlmeier JE, Parkos CA, Towne JE, Nusrat A, Denning TL.

J Immunol. 2016 Jan 1;196(1):34-8. doi: 10.4049/jimmunol.1501312.

6.

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.

Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, Stevens E, Bigler J, Davis JA, Rottman JB, Budelsky AL, Symons A, Towne JE.

Immunity. 2015 Oct 20;43(4):739-50. doi: 10.1016/j.immuni.2015.08.019.

7.

Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions.

Gabay C, Towne JE.

J Leukoc Biol. 2015 Apr;97(4):645-52. doi: 10.1189/jlb.3RI1014-495R. Review.

8.

Elimination of Pasteurella pneumotropica from a mouse barrier facility by using a modified enrofloxacin treatment regimen.

Towne JW, Wagner AM, Griffin KJ, Buntzman AS, Frelinger JA, Besselsen DG.

J Am Assoc Lab Anim Sci. 2014 Sep;53(5):517-22.

9.

Preclinical development of AMG 139, a human antibody specifically targeting IL-23.

Köck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, Goletz TJ, Newhall KJ, Rees WA, Sun Y, Zhang Y, O'Neill JC, Umble-Romero AN, Prokop SP, Krill CD, Som L, Buntich SA, Trimble MW, Tsuji WH, Towne JE.

Br J Pharmacol. 2015 Jan;172(1):159-72. doi: 10.1111/bph.12904.

10.

Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.

Derer A, Groetsch B, Harre U, Böhm C, Towne J, Schett G, Frey S, Hueber AJ.

PLoS One. 2014 Aug 11;9(8):e101954. doi: 10.1371/journal.pone.0101954.

11.

Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.

von Scheidt B, Leung PS, Yong MC, Zhang Y, Towne JE, Smyth MJ, Teng MW.

Cancer Res. 2014 May 1;74(9):2412-21. doi: 10.1158/0008-5472.CAN-13-1646.

12.

The severity of experimental arthritis is independent of IL-36 receptor signaling.

Lamacchia C, Palmer G, Rodriguez E, Martin P, Vigne S, Seemayer CA, Talabot-Ayer D, Towne JE, Gabay C.

Arthritis Res Ther. 2013 Mar 1;15(2):R38. doi: 10.1186/ar4192.

13.

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG.

Trends Immunol. 2013 Apr;34(4):174-81. doi: 10.1016/j.it.2012.11.005. Review.

14.

Long-term comparison of endovascular and open repair of abdominal aortic aneurysm.

Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT Jr, Kohler TR, Kougias P, Jean-Claude JM, Cikrit DF, Swanson KM; OVER Veterans Affairs Cooperative Study Group..

N Engl J Med. 2012 Nov 22;367(21):1988-97. doi: 10.1056/NEJMoa1207481.

15.

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ.

Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337.

16.

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.

Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB.

J Invest Dermatol. 2013 Jan;133(1):17-26. doi: 10.1038/jid.2012.194. Review.

17.

Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial.

Stroupe KT, Lederle FA, Matsumura JS, Kyriakides TC, Jonk YC, Ge L, Freischlag JA; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group..

J Vasc Surg. 2012 Oct;56(4):901-9.e2. doi: 10.1016/j.jvs.2012.01.086.

18.

IL-36 in psoriasis.

Towne JE, Sims JE.

Curr Opin Pharmacol. 2012 Aug;12(4):486-90. doi: 10.1016/j.coph.2012.02.009. Review.

PMID:
22398321
19.

Are Th17 cells in the gut pathogenic or protective?

Symons A, Budelsky AL, Towne JE.

Mucosal Immunol. 2012 Jan;5(1):4-6. doi: 10.1038/mi.2011.51.

PMID:
22071661
20.

Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.

Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, Sims JE.

J Biol Chem. 2011 Dec 9;286(49):42594-602. doi: 10.1074/jbc.M111.267922.

Items per page

Supplemental Content

Loading ...
Support Center